In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection

Keyphrases

• Clinically Significant 100%
• Clostridioides Difficile 100%
• Cadazolid 100%
• C.difficile Infection 100%
• In Vitro Activity 100%
• Intestinal Epithelial Cells 100%
• Difficile 45%
• Moxifloxacin 36%
• Linezolid 36%
• Gut Model 18%
• Gut Microflora 18%
• Vancomycin 18%
• Resistant Isolate 18%
• Metronidazole 18%
• Cytotoxin 18%
• Dosing Regimen 18%
• Antimicrobial 18%
• Viable Count 9%
• Bifidobacterium 9%
• Geometric Mean 9%
• Ribotype 027 9%
• Metronidazole Susceptibility 9%
• Lactobacillus Spp 9%
• Human Gut 9%
• Microflora Population 9%
• Titre 9%
• Twice Daily 9%
• Epidemic Strain 9%
• Quinolones 9%
• Quinolone Resistance 9%
• Linezolid Resistance 9%
• Resistance Emergence 9%
• Total Viable Count 9%
• MIC90 9%
• Bacteroides Fragilis Group 9%
• Linezolid-resistant 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Clostridium Difficile Infection 100%
• Cadazolid 100%
• Peptoclostridium difficile 100%
• Linezolid 54%
• Moxifloxacin 36%
• Metronidazole 27%
• Microflora 27%
• Recurrent Disease 18%
• Cytotoxin 18%
• Vancomycin 18%
• Agar 9%
• Bacteroides fragilis 9%
• Lactobacillus 9%
• Bifidobacterium 9%
• Quinolone 9%
• Quinolone Derivative 9%
• Antiinfective Agent 9%

Immunology and Microbiology

• Peptoclostridium difficile 100%
• Microflora 100%
• Minimum Inhibitory Concentration 66%
• Lactobacillus 33%
• Viable Cell Count 33%
• Agar 33%
• MIC90 33%
• Bacteroides fragilis 33%
• Bifidobacterium 33%
• Total Viable Count 33%